Skip to main content
    PeptideAuthority
    EK

    Dr Elena Kowalski, MSc, PhD

    Molecular Biology and Immunology — Imperial College London

    Profile last reviewed: 2026-05-20

    Dr Kowalski specialises in immune peptide research, with publications on thymosin alpha-1 and antimicrobial peptides. She reviews our immunology content and ensures our safety information reflects current research.

    Credentials

    • MSc, Molecular Biology
    • PhD, Molecular Biology — Imperial College London
    • Published research on thymosin alpha-1 and antimicrobial peptides

    Professional registrations

    • Royal Society of Biology: Member
    • British Society for Immunology: Member

    Academic and learned-society registrations only. No clinical prescribing registration applies to this reviewer's role.

    Role on the editorial board

    Lead reviewer for immune-modulating and antimicrobial peptide content. Reviews thymosin family, LL-37, KPV, defensins, and related immunology claims across the peptide library and the immune-and-inflammation hub.

    Conflict of interest disclosures

    • No equity in peptide manufacturers, immunology-product companies, or online clinics.
    • No paid consulting arrangements with companies that market the peptides reviewed.
    • Has received public-sector research funding (UKRI / Wellcome) for unrelated immunology work; disclosed transparently.

    Disclosures are reviewed annually and updated at the date shown above. See the conflict-of-interest policy for the wider framework.

    Sections reviewed

    • All immune-modulating peptide profiles (thymosin alpha-1, LL-37, KPV, defensins, etc.)
    • Immune and Inflammation hub and spokes
    • Autoimmune-conditions and long-COVID guides

    Citation policy

    Immunology claims must trace to peer-reviewed literature. Mechanism claims are clearly separated from clinical-outcome claims. Where licensed-medicine evidence exists in non-UK markets (e.g. thymosin alpha-1 in parts of Europe), the regulatory boundary is stated explicitly.

    The site-wide methodology is documented in our evidence grading methodology and editorial standards.

    About the editorial board

    Peptide Authority’s editorial board is responsible for the accuracy, evidence-grading, and UK regulatory framing of the content on this site. Read more about how we work in editorial standards and the corrections policy.

    Other reviewers